Assembly Biosciences, Inc. (ASMB) Financial Analysis & Valuation | Quarter Chart
Assembly Biosciences, Inc. (ASMB)
ASMBPrice: $31.96
Fair Value: 🔒
🔒score
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat ... more
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeut... more
Description
Shares
| Market Cap | $245.20M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jason A. Okazaki |
| IPO Date | 2010-12-17 | CAGR | — |
| Employees | 73 | Website | www.assemblybio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ASMB chart loading...
Fundamentals
Technicals
| Enterprise Value | $117.60M | P/E Ratio | -5.61 |
| Forward P/E | -11.4 | PEG Ratio | — |
| P/S Ratio | 10.38 | P/B Ratio | 13.52 |
| P/CF Ratio | -4.38 | P/FCF Ratio | -4.39 |
| EPS | $-5.56 | EPS Growth 1Y | -30.91% |
| EPS Growth 3Y | 78.34% | EPS Growth 5Y | 244.42% |
| Revenue Growth 1Y | -6.79% | Gross Margin | 1% |
| Operating Margin | -1.84% | Profit Margin | -1.65% |
| ROE | -1.49% | ROA | -0.48% |
| ROCE | -1.3% | Current Ratio | 1.64 |
| Quick Ratio | 1.64 | Cash Ratio | 0.51 |
| Debt/Equity | 0.16 | Interest Coverage | — |
| Altman Z Score | -13.4 | Piotroski Score | 1 |